Kymera Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Kymera Therapeutics sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 4 currently recruiting 6 completed early-phase tilt top decile by trial count

Kymera Therapeutics: 10 sponsored US clinical trials, 4 recruiting.

Kymera Therapeutics sponsors 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atopic Dermatitis, with 2 trials.

Top-decile sponsor footprint

Kymera Therapeutics ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

NCT07677059
RECRUITING Phase 1

First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants

NCT07412288
RECRUITING Phase 2

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

NCT07323654
RECRUITING Phase 2

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

NCT07217015
COMPLETED Phase 1

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

NCT06945458
COMPLETED Phase 1

First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants

NCT06673667
COMPLETED Phase 1

Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

NCT05775406
COMPLETED Phase 1

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

NCT05233033
COMPLETED Phase 1

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

NCT05225584
COMPLETED Phase 1

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

NCT04772885

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 3

Therapeutic Areas

Atopic Dermatitis 2
MYD88 Gene Mutation 1
Eosinophilic Asthma 1
DLBCL 1
Non-Hodgkin Lymphoma 1
Diffuse Large B Cell Lymphoma 1
Healthy Participants 1

What is open in the Kymera Therapeutics pipeline

4 recruiting of 10 indexed (40% open); 6 completed (60%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Atopic Dermatitis (2 trials), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Kymera Therapeutics: open-pipeline peers nationwide

Peers matched on 10 registered trials and 40% open enrollment, not the therapeutic-area sidebar.

Kymera Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%10%20%30%40%50% Total trials Recruiting share Kymera TherapeuticsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAd scientiamAlto NeuroscienceBonafide HealthBrooks Rehabilitation
Kymera Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kymera Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 40% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Kymera Therapeutics page

10 registered trials is a research-attention snapshot, not an endorsement of Kymera Therapeutics or any single study.

  • 4 of Kymera Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Atopic Dermatitis is the condition Kymera Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atopic Dermatitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Kymera Therapeutics pipeline card: 10 registered trials from official public datasets.Report a data error.